NASDAQ:DMAC - DiaMedica Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $24.00
  • Forecasted Upside: 1,088.12 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.02
▼ -0.05 (-2.42%)

This chart shows the closing price for DMAC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DiaMedica Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DMAC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DMAC

Analyst Price Target is $24.00
▲ +1,088.12% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for DiaMedica Therapeutics in the last 3 months. The average price target is $24.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 1,088.12% upside from the last price of $2.02.

This chart shows the closing price for DMAC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in DiaMedica Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/10/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/9/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2021Roth CapitalLower Price TargetBuy$32.00 ➝ $24.00Low
6/30/2021Maxim GroupLower Price TargetBuy$14.00 ➝ $11.00High
6/29/2021Roth CapitalLower Price TargetBuy$38.00 ➝ $32.00High
4/8/2021OppenheimerInitiated CoverageOutperform$27.00High
3/15/2021Craig HallumBoost Price Target$15.00 ➝ $20.00Medium
2/17/2021Roth CapitalInitiated CoverageBuy$38.00Low
1/4/2021Lake Street CapitalBoost Price TargetBuy$14.00 ➝ $28.00N/A
10/30/2020GuggenheimInitiated CoverageBuy$16.00High
8/13/2020Maxim GroupReiterated RatingBuyLow
7/8/2020Maxim GroupInitiated CoverageBuy$14.00Medium
5/15/2020Craig HallumBoost Price TargetBuy$10.00 ➝ $15.00High
5/15/2020Lake Street CapitalBoost Price TargetBuy$9.00 ➝ $14.00Medium
6/20/2019Craig HallumBoost Price TargetBuy$9.00 ➝ $11.00High
4/30/2019Dougherty & CoInitiated CoverageBuy ➝ Buy$8.00Low
3/5/2019Lake Street CapitalInitiated CoverageBuy$9.00High
1/3/2019Craig HallumInitiated CoverageBuyN/A
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/7/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/6/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
DiaMedica Therapeutics logo
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Read More

Today's Range

Now: $2.02
Low: $1.96
High: $2.04

50 Day Range

MA: $2.32
Low: $1.86
High: $2.62

52 Week Range

Now: $2.02
Low: $1.62
High: $4.82

Volume

19,505 shs

Average Volume

59,477 shs

Market Capitalization

$53.41 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.28

Frequently Asked Questions

What sell-side analysts currently cover shares of DiaMedica Therapeutics?

The following sell-side analysts have issued reports on DiaMedica Therapeutics in the last twelve months: Roth Capital.
View the latest analyst ratings for DMAC.

What is the current price target for DiaMedica Therapeutics?

0 Wall Street analysts have set twelve-month price targets for DiaMedica Therapeutics in the last year. Their average twelve-month price target is $24.00, suggesting a possible upside of 1,088.1%.
View the latest price targets for DMAC.

What is the current consensus analyst rating for DiaMedica Therapeutics?

DiaMedica Therapeutics currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DMAC will outperform the market and that investors should add to their positions of DiaMedica Therapeutics.
View the latest ratings for DMAC.

How do I contact DiaMedica Therapeutics' investor relations team?

DiaMedica Therapeutics' physical mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The company's listed phone number is (763) 312-6755 and its investor relations email address is [email protected] The official website for DiaMedica Therapeutics is www.diamedica.com. Learn More about contacing DiaMedica Therapeutics investor relations.